Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing adenosine or derivative of adenosine

A pharmaceutical composition and composition technology, applied in the field of pharmaceutical compositions containing adenosine or its derivatives, capable of solving problems such as liver damage

Inactive Publication Date: 2013-11-13
NANJING UNIV OF SCI & TECH
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

When the drug is used in large amounts or for too long, it can cause damage to the liver

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing adenosine or derivative of adenosine
  • Pharmaceutical composition containing adenosine or derivative of adenosine
  • Pharmaceutical composition containing adenosine or derivative of adenosine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089] (1) Animal model

[0090]The experimental animals were eight-week-old male C57BL / 6 (WT) mice. Raised under standard experimental conditions: 12-hour light-12-hour dark cycle, free access to water and food. The pharmaceutical composition containing adenosine or its derivatives and anti-tuberculosis drugs is administered through intragastric administration. WT mice were randomly divided into 7 groups. Group 0 was defined as the control group, and the corresponding drug medium was treated during the experiment; It is a combination group of adenosine or its derivatives and rifampicin, and is divided into 12 groups from 2a to 2l, respectively:

[0091] Group 2a administered the adenosine and rifampicin composition (11.1mg / kg:100mg / kg, 1:9) by intragastric administration,

[0092] Group 2b administered a combination of adenosine and rifampicin (100mg / kg:100mg / kg, 1:1) by intragastric administration,

[0093] Group 2c administered the adenosine and rifampicin composition (...

Embodiment 2

[0115] (1) Animal model

[0116] The experimental animals were eight-week-old male C57BL / 6 (WT) mice. Raised under standard experimental conditions: 12-hour light-12-hour dark cycle, free access to water and food. The pharmaceutical composition containing adenosine or its derivatives and antipyretic, analgesic and anti-inflammatory drugs is administered through intragastric administration. WT mice were randomly divided into 13 groups, and group 0 was defined as the control group, and the corresponding drug medium was treated during the experiment; group 1 was the acetaminophen group, and acetaminophen (300 mg / kg) was administered by intragastric administration; Group 2 is the combination group of adenosine or its derivatives and acetaminophen, and is divided into 12 groups from 2a to 2l, respectively:

[0117] Group 2a administered adenosine and acetaminophen composition (33.3mg / kg:300mg / kg, 1:9) by intragastric administration,

[0118] Group 2b administered the adenosine a...

Embodiment 3

[0140] (1) Animal model

[0141] The experimental animals were eight-week-old male C57BL / 6 (WT) mice. Raised under standard experimental conditions: 12-hour light-12-hour dark cycle, free access to water and food. The pharmaceutical composition containing adenosine or its derivatives and treating psychosis is administered through intragastric administration. WT mice were randomly divided into 13 groups, and group 0 was defined as the control group, which was treated with the corresponding drug medium during the experiment; group 1 was the carbamazepine group, and carbamazepine (300 mg / kg) was administered by intragastric administration; group 2 It is a combination group of adenosine or its derivatives and carbamazepine, and is divided into 12 groups from 2a to 2l, respectively:

[0142] Group 2a administered adenosine and carbamazepine composition (33.3mg / kg:300mg / kg, 1:9) by intragastric administration,

[0143] Group 2b administered adenosine and carbamazepine composition...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition containing adenosine or derivatives of adenosine. The pharmaceutical composition comprises a composition of adenosine or the derivatives of adenosine and clinically compounds which lead to liver injury. The derivatives of adenosine are adenosine monophosphate, adenosine diphosphate or adenosine triphosphate. The clinically compounds which lead to liver injury comprise compounds for treating tuberculosis, antipyretic, analgesic and anti-inflammatory compounds, compounds for treating mental diseases, antibacterial compounds, hormonic compounds or anti-tumor compounds. The mouse model adopted by the invention is a mouse acute liver injury model induced by the compounds which lead to liver injury. The mass ratio of adenosine or the derivatives of adenosine and the compounds in the composition is (1:9)-(9:1). The pharmaceutical composition containing adenosine or the derivatives of adenosine and the compounds can reduce activity of AST (Aspartate Amino Transferase) and ALT (Alanine Amino Transferase) in liver injury and reduce necrosis area of parenchyma cells of liver, so that liver injury caused by the compounds is alleviated. The pharmaceutical composition disclosed by the invention shows that adenosine or the derivative of adenosine has protective effect on liver injury caused by the compounds.

Description

technical field [0001] The invention belongs to the technical field of medicine, and the invention relates to a medicine composition containing adenosine or its derivatives. Background technique [0002] The liver is one of the important organs in mammals. It is also called "processing plant" because of its functions of synthesis, detoxification, metabolism, secretion, biotransformation and immune defense. The liver is the main organ for drug concentration, transformation, and metabolism, especially oral drugs enter the liver after being absorbed by the gastrointestinal tract, and the concentration in the liver is higher than that in the blood and other organs. When the dosage of the drug is too large or the medication time is too long, it will cause damage to the liver. Especially when two or more drugs are combined inappropriately, the damage will be even worse, causing some liver cell necrosis, jaundice, elevated serum alanine aminotransferase and other abnormal liver fu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/7076A61P1/16A61P31/06A61P29/00A61P25/18A61P31/04A61P5/00A61P35/00
Inventor 张建法詹亦贝王涛周梦怡
Owner NANJING UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products